Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Avacta Group plc
DescriptionFragment crystallisable (Fc) region of an antibody fusions against programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274)
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionProgrammed cell death 1 (PD-1) antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today